Abstract
Behçet’s disease (BD) is a chronic, multi-system inflammatory disease with potentially devastating ocular involvement. Uveitis remains one of the leading causes of blindness in BD patients. The usual remedies, mainly corticosteroids and immunosuppressants, do not effectively work long term and/or stop relapses. New medicines have changed treatment. New therapies for Behçet’s uveitis may just address the cause of the disease process. This paper analyses the continuous evolution of biologics and their contribution towards improving prognosis; specifically it examines tumour necrosis factor (TNF) inhibitors, interleukin (IL) antagonists, and other monoclonal antibodies. Drugs like infliximab and adalimumab have been quite helpful in controlling inflammation, preventing relapses, and saving sight. These agents target immune pathways to ameliorate the systemic and ocular manifestations of BD, and they have a better safety profile than traditional agents. Rising proof points out that IL-17 and IL-1 inhibitors may also work, opening the choice of therapy for resistant cases. Even though they have made progress, there is still a lot of work to do and overcome optimization biologics challenges related to the patient, cost, and adverse effects. This review highlights the value of personalized treatments, offering key recommendations for the use of biologics in their overall management approach depending on the severity. Also, real-world studies and head-to-head trials will help refine therapeutic algorithms in the future directions. Doctors may use biologic therapies to greatly enhance the quality of life and the visual outcome in Behçet’s uveitis. It is an important step toward precision medicine in BD.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call